Joseph Stringer

Shares of Cara Therapeutics Inc (NASDAQ:CARA) tanked in early trading on Thursday, with the Dow shedding more than 100 points. The company reported its quarterly results amid an exciting earnings season. Here are some key analyst takeaways. Needham analyst Joseph Stringer downgraded the rating on...

Moderna, Inc. (NASDAQ: MRNA) reported better-than-expected fourth-quarter earnings Thursday and announced a slight upward revision to its vaccine sales forecast for 2022. The company also announced a $3-billion stock buyback. The stock rallied 15.1% in Thursday's trading session. Here's...

Moderna, Inc. (NASDAQ: MRNA) shares are picking up momentum after a steep sell-off on Monday, triggered by a scientific publication that suggested booster doses are unwarranted at this point of time. The company released a statement Wednesday that said incremental data from the Phase 3 COVE...

Cara Therapeutics Inc (NASDAQ: CARA) stock spiked 34 percent Wednesday after the company reported that a Phase 2/3 trial for intravenous CR845 met primary and secondary endpoints. The investor bullishness resonated with Needham.  The Rating Needham analyst Alan Carr maintained a...